We are exploring the genetic and epigenetic mechanisms underlying lethal cancers of the genitourinary tract with the goal of translating discovery in to novel therapies. Our approach couples translational research to clinical investigation in GU malignancies at Cleveland Clinic's Lerner Research Institute. We are developing powerful tools for identifying predictive and prognostic biomarkers as well as for therapeutic target discovery. The mission of our lab is to reduce the burden of prostate and bladder cancer through fundamental discovery and to improve the lives of cancer patients.
Molecular profiling of Neuroendocrine/Small Cell Bladder Cancer
Developing new model systems to explore the epigenetic cofactors that promote neuroendocrine transdifferentiation.
Identifying biomarkers and dissecting combinatorial synergies to improve immune checkpoint inhibitor response in bladder cancer.
Investigating the role of CpG methylation readers, writers, and erasers in tumor initiation and progression.
Targeting HSD3B1 associated extragonadal androgen biosynthesis.
We are grateful for support from: